Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pharma giant Celgene finally confirms USD 9 billion Juno Therapeutics buyout Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that is expected to get the FDA approval next year with an estimated market potential of around USD 3 billion. Eureka bags a funding of USD 60 million to take T-cell therapy into the clinical trials Eureka Therapeutics is heading forward with full swing after getting USD 60 million in series D round. The funding will facilitate the phase I development of compan...